Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

被引：0
|
作者：
Jean-Luc Van Laethem
Hanno Riess
Jacek Jassem
Michael Haas
Uwe M. Martens
Colin Weekes
Marc Peeters
Paul Ross
John Bridgewater
Bohuslav Melichar
Stefano Cascinu
Piotr Saramak
Patrick Michl
David Van Brummelen
Alberto Zaniboni
Wollf Schmiegel
Svein Dueland
Marius Giurescu
Vittorio L. Garosi
Katrin Roth
Anke Schulz
Henrik Seidel
Prabhu Rajagopalan
Michael Teufel
Barrett H. Childs
机构：
[1] Erasme University Hospital,Department of Gastroenterology
[2] Charity Hospital,Medical Department, Division of Hematology, Oncology and Tumor Immunology
[3] Virchow-Klinikum Campus,Department of Oncology and Radiotherapy
[4] Medical University of Gdansk,Department of Hematology and Oncology
[5] University of Munich Medical Center,Department of Hematology and Oncology
[6] Cancer Center Heilbronn-Franken,Division of Medical Oncology
[7] University of Colorado Cancer Center,Department of Oncology
[8] Antwerp University Hospital,Department of Medical Oncology
[9] Guy’s & St Thomas’ Hospital,Department of Oncology
[10] UCL Cancer Institute,Department of Oncology
[11] Palacky University Medical School and University Hospital Olomouc,Department of Medical Oncology, A.O.U. United Hospitals
[12] Polytechnic University of Marche,Department of Oncological Gastroenterology
[13] Maria Skłodowska-Curie Memorial Cancer Center,Department of Gastroenterology, Endocrinology, Metabolism and Infectiology
[14] University Hospital of Giessen and Marburg,Department of Radiotherapy
[15] Universitätsklinikum Halle - University Hospital Halle (Saale),Department of Medical Oncology
[16] UZ Brussels,Department of Gastroenterology and Hepatology
[17] Poliambulanza Foundation Hospital Institute,Department of Oncology
[18] Medical University Hospital Bochum,undefined
[19] Oslo University Radium Hospital,undefined
[20] Bayer Pharma AG,undefined
[21] Bayer S.p.A.,undefined
[22] Bayer HealthCare Pharmaceuticals,undefined
[23] Inc.,undefined
来源：
Targeted Oncology | 2017年 / 12卷
关键词：
Gemcitabine; Objective Response Rate; KRAS Mutation; Disease Control Rate; Advanced Pancreatic Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 109
页数：12
相关论文
共 50 条
  • [1] Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
    Laethem, Jean-Luc Van
    Riess, Hanno
    Jassem, Jacek
    Haas, Michael
    Martens, Uwe M.
    Weekes, Colin
    Peeters, Marc
    Ross, Paul
    Bridgewater, John
    Melichar, Bohuslav
    Cascinu, Stefano
    Saramak, Piotr
    Michl, Patrick
    Van Brummelen, David
    Zaniboni, Alberto
    Schmiegel, Wollf
    Dueland, Svein
    Giurescu, Marius
    Garosi, Vittorio L.
    Roth, Katrin
    Schulz, Anke
    Seidel, Henrik
    Rajagopalan, Prabhu
    Teufel, Michael
    Childs, Barrett H.
    TARGETED ONCOLOGY, 2017, 12 (01) : 97 - 109
  • [2] Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.
    Riess, Hanno
    Van Laethem, Jean-Luc
    Martens, Uwe Marc
    Heinemann, Volker
    Michl, Patrick
    Peeters, Marc
    Van Brummelen, David
    Weekes, Colin D.
    Dueland, Svein
    Schmiegel, Wolff H.
    Giurescu, Marius
    Garosi, Vittorio Luigi
    Schulz, Anke
    Seidel, Henrik
    Childs, Barrett H.
    Teufel, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.
    Van Laethem, Jean-Luc
    Jassem, Jacek
    Heinemann, Volker
    Weekes, Colin D.
    Bridgewater, John A.
    Cascinu, Stefano
    Melichar, Bohuslav
    Peeters, Marc
    Ross, Paul J.
    Saramak, Piotr
    Giurescu, Marius
    Garosi, Vittorio Luigi
    Roth, Katrin
    Schulz, Anke
    Teufel, Michael
    Childs, Barrett H.
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.
    Van Laethem, Jean-Luc
    Heinemann, Volker
    Martens, Uwe Marc
    Jassem, Jacek
    Michl, Patrick
    Peeters, Marc
    Weekes, Colin D.
    Marechal, Raphael
    Stieler, Jens
    Giurescu, Marius
    Rajagopalan, Prabhu
    Garosi, Vittorio Luigi
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
    Lim, Ho Yeong
    Heo, Jeong
    Choi, Hye Jin
    Lin, Cheng-Yao
    Yoon, Jung-Hwan
    Hsu, Chiun
    Rau, Kun-Ming
    Poon, Ronnie T. P.
    Yeo, Winnie
    Park, Joong-Won
    Tay, Miah Hiang
    Hsieh, Wen-Son
    Kappeler, Christian
    Rajagopalan, Prabhu
    Krissel, Heiko
    Jeffers, Michael
    Yen, Chia-Jui
    Tak, Won Young
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5976 - 5985
  • [6] Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
    Weekes, Colin D.
    Von Hoff, Daniel D.
    Adjei, Alex A.
    Leffingwell, Diane P.
    Eckhardt, S. Gail
    Gore, Lia
    Lewis, Karl D.
    Weiss, Glen J.
    Ramanathan, Ramesh K.
    Dy, Grace K.
    Ma, Wen W.
    Sheedy, Beth
    Iverson, Cory
    Miner, Jeffrey N.
    Shen, Zancong
    Yeh, Li-Tain
    Dubowy, Ronald L.
    Jeffers, Michael
    Rajagopalan, Prabhu
    Clendeninn, Neil J.
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1232 - 1243
  • [7] Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.
    Gore, L.
    Lewis, K.
    Von Hoff, D. D.
    Weiss, G. J.
    Ramanathan, R. K.
    Adjei, A. A.
    Dy, G. K.
    Ma, W. W.
    Clendeninn, N. J.
    Leffingwell, D. P.
    Sheedy, B.
    Iverson, C.
    Miner, J. N.
    Shen, Z.
    Yeh, L.
    Dubowy, R. L.
    Jeffers, M.
    Rajagopalan, P.
    Weekes, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] The MEK Inhibitor BAY 86-9766 Prolongs Survival in Orthotopic, Syngeneic Animal Models of Hepatocellular Carcinoma and Pancreatic Cancer
    Schmieder, R.
    Puehler, F.
    Neuhaus, R.
    Mumberg, D.
    Ziegelbauer, K.
    Scholz, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S231 - S231
  • [9] A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Eskens, Ferry
    Blumenschein, George R.
    Richards, Donald A.
    Renshaw, Frank Gary
    Rajagopalan, Prabhu
    Kelly, Andrea
    Pena, Carol Elaine
    Mross, Klaus B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer
    Okusaka, Takuji
    Ishii, Hiroshi
    Funakoshi, Akihiro
    Ueno, Hideki
    Furuse, Junji
    Sumii, Toshihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (09) : 557 - 563
12345